Vein Graft Articles & Analysis
8 news found
A lower extremity bypass procedure - like any surgery - can be more difficult as we age. The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young ...
The GOAL Study is an independent investigator observational clinical study to assess the role of vascular graft /storage solutions on myocardial protection during coronary artery bypass grafting (CABG) surgeries. ...
These patents protect Marizyme’s flagship commercial product DuraGraft®, a first-in-class CE marked intra-operative graft storage solution. DuraGraft® protects vascular grafts against ischemic injury during bypass surgeries by reducing the incidence of complications associated with vein graft failure, leading to ...
The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) ...
"DuraGraft will enhance coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction, providing better patient care, and potentially lowering the impact on the overall cost of health care in CABG procedures." ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. ...
Abel Alexander, Regency Lifesciences CEO, said, "This approval and licensure represents a significant step toward providing this novel treatment to the estimated 60,000 Coronary Artery Bypass Graft Surgeries per year." About CABG and DuraGraft When patients with heart disease undergo CABG surgery, free vein or arterial grafts harvested from the ...